Val-BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine Tumors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Val-BoroPro Accelerates T Cell Priming via Modulation of Dendritic Cell Trafficking Resulting in Complete Regression of Established Murine Tumors
Authors
Keywords
Cancer treatment, T cells, Lymph nodes, Dendritic cells, Immune response, Chemokines, Cytotoxic T cells, Vaccines
Journal
PLoS One
Volume 8, Issue 3, Pages e58860
Publisher
Public Library of Science (PLoS)
Online
2013-03-13
DOI
10.1371/journal.pone.0058860
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Defective MHC Class II Presentation by Dendritic Cells Limits CD4 T Cell Help for Antitumor CD8 T Cell Responses
- (2014) M. Y. Gerner et al. JOURNAL OF IMMUNOLOGY
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Th17 differentiation is the default program for DPP2-deficient T-cell differentiation
- (2011) Deanna A. Mele et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy
- (2011) Joanna L. Meadors et al. PEDIATRIC BLOOD & CANCER
- Incretin-Based Therapies: Review of Current Clinical Trial Data
- (2010) Anne Peters AMERICAN JOURNAL OF MEDICINE
- Pediatric Phase I Trial Design Using Maximum Target Inhibition as the Primary Endpoint
- (2010) Holly Meany et al. JNCI-Journal of the National Cancer Institute
- Lipid accumulation and dendritic cell dysfunction in cancer
- (2010) Donna L Herber et al. NATURE MEDICINE
- Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-
- (2010) M. Kraman et al. SCIENCE
- Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
- (2009) Robert M Eager et al. BMC CANCER
- Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
- (2009) Angela Pennisi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches
- (2009) Terry J. Fry et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
- (2009) R.M. Eager et al. CLINICAL ONCOLOGY
- In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb
- (2009) Oihana Murillo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
- (2009) Angélica M. Santos et al. JOURNAL OF CLINICAL INVESTIGATION
- Antigen Processing and MHC-II Presentation by Dermal and Tumor-Infiltrating Dendritic Cells
- (2009) M. Y. Gerner et al. JOURNAL OF IMMUNOLOGY
- Enhancing the efficacy of cancer vaccines in urologic oncology: new directions
- (2009) Sergei Kusmartsev et al. Nature Reviews Urology
- HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat
- (2008) Anthony D. Cristillo et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Factor
- (2008) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunotherapy
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity
- (2008) K. Hildner et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now